{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:07:24Z","timestamp":1788570444528,"version":"build-2803163510"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40273-023-01318-y","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T12:02:45Z","timestamp":1695729765000},"page":"41-68","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2691-2692","authenticated-orcid":false,"given":"Melissa","family":"Lannon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Duda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Mastrolonardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellissa","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Martyniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forough","family":"Farrokhyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneil K.","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunjay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"1318_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/309431","volume":"2012","author":"EA Shipton","year":"2012","unstructured":"Shipton EA. Movement disorders and neuromodulation. Neurol Res Int. 2012;2012: 309431.","journal-title":"Neurol Res Int"},{"key":"1318_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/B978-0-444-53497-2.00009-7","volume":"116","author":"P Pollak","year":"2013","unstructured":"Pollak P. Deep brain stimulation for Parkinson\u2019s disease: patient selection. Handb Clin Neurol. 2013;116:97\u2013105.","journal-title":"Handb Clin Neurol"},{"key":"1318_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.57.4.663","volume":"57","author":"KJ Tomaszewski","year":"2001","unstructured":"Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson\u2019s disease: a cost-effectiveness analysis. Neurology. 2001;57:663\u201371.","journal-title":"Neurology"},{"key":"1318_CR4","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40273-015-0309-4","volume":"33","author":"JF O\u2019Mahony","year":"2015","unstructured":"O\u2019Mahony JF, Newall AT, van Rosmalen J. Dealing with time in health economic evaluation: methodological issues and recommendations for practice. Pharmacoeconomics. 2015;33:1255\u201368.","journal-title":"Pharmacoeconomics"},{"key":"1318_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/mdc3.12755","volume":"6","author":"N Afentou","year":"2019","unstructured":"Afentou N, Jarl J, Gerdtham U-G, Saha S. Economic evaluation of interventions in Parkinson\u2019s disease: a systematic literature review. Mov Disord Clin Pract. 2019;6:282\u201390.","journal-title":"Mov Disord Clin Pract."},{"key":"1318_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.wneu.2016.05.028","volume":"93","author":"JE Becerra","year":"2016","unstructured":"Becerra JE, Zorro O, Ruiz-Gaviria R, Casta\u00f1eda-Cardona C, Ot\u00e1lora-Esteban M, Henao S, et al. Economic analysis of deep brain stimulation in Parkinson disease: systematic review of the literature. World Neurosurg. 2016;93:44\u20139.","journal-title":"World Neurosurg."},{"key":"1318_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01289-0","author":"J Dams","year":"2023","unstructured":"Dams J, Zapp J-J, K\u00f6nig H-H. Modelling the cost effectiveness of treatments for Parkinson\u2019s disease: an updated methodological review. Pharmacoeconomics. 2023. https:\/\/doi.org\/10.1007\/s40273-023-01289-0.","journal-title":"Pharmacoeconomics"},{"key":"1318_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/mdc3.12780","volume":"6","author":"TTH Dang","year":"2019","unstructured":"Dang TTH, Rowell D, Connelly LB. Cost-effectiveness of deep brain stimulation with movement disorders: a systematic review. Mov Disord Clin Pract. 2019;6:348\u201358.","journal-title":"Mov Disord Clin Pract."},{"key":"1318_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1471-2288-14-139","volume":"14","author":"C Crespo","year":"2014","unstructured":"Crespo C, Monleon A, D\u00edaz W, R\u00edos M. Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies. BMC Med Res Methodol. 2014;14:139.","journal-title":"BMC Med Res Methodol"},{"key":"1318_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12913-022-07595-1","volume":"22","author":"BS Bagepally","year":"2022","unstructured":"Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, Attia J, Thakkinstian A. Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. BMC Health Serv Res. 2022;22:202.","journal-title":"BMC Health Serv Res"},{"key":"1318_CR11","doi-asserted-by":"publisher","first-page":"ofz117","DOI":"10.1093\/ofid\/ofz117","volume":"6","author":"S Haider","year":"2019","unstructured":"Haider S, Chaikledkaew U, Thavorncharoensap M, Youngkong S, Islam MA, Thakkinstian A. Systematic review and meta-analysis of cost-effectiveness of rotavirus vaccine in low-income and lower-middle-income countries. Open Forum Infect Dis. 2019;6:ofz117.","journal-title":"Open Forum Infect Dis"},{"key":"1318_CR12","unstructured":"Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia; 2022. Available from: http:\/\/www.covidence.org. Accessed 12 Sep 2023."},{"key":"1318_CR13","unstructured":"World Economic Outlook Database. International Monetary Fund; 2022. Available from: https:\/\/www.imf.org\/en\/Publications\/WEO\/weo-database\/2022\/October\/download-entire-database. Accessed 12 Sep 2023."},{"key":"1318_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"1318_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1017\/S0266462305050324","volume":"21","author":"S Evers","year":"2005","unstructured":"Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005;21:240\u20135.","journal-title":"Int J Technol Assess Health Care"},{"key":"1318_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/14737167.2016.1246961","volume":"16","author":"B Wijnen","year":"2016","unstructured":"Wijnen B, Van Mastrigt G, Redekop W, Majoie H, De Kinderen R, Evers S. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3\/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16:723\u201332.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1318_CR17","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2165\/00019053-200422130-00004","volume":"22","author":"R Welte","year":"2004","unstructured":"Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics. 2004;22:857\u201376.","journal-title":"Pharmacoeconomics"},{"key":"1318_CR18","unstructured":"ISPOR. Pharmacoeconomic guidelines: United States of America. 2022. Available from: https:\/\/www.ispor.org\/heor-resources\/more-heor-resources\/pharmacoeconomic-guidelines\/pe-guideline-detail\/united-states-of-america. Accessed 9 Mar 2023."},{"key":"1318_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-effectiveness in health and medicine","author":"M Gold","year":"1996","unstructured":"Gold M, Siegel J, Russel L, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996."},{"key":"1318_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/(SICI)1099-1050(1998110)7:7<629::AID-HEC378>3.0.CO;2-N","volume":"7","author":"K Schulman","year":"1998","unstructured":"Schulman K, Burke J, Drummond M, Davies L, Carlsson P, Gruger J, et al. Resource costing for multinational neurologic clinical trials: methods and results. Health Econ. 1998;7:629\u201338.","journal-title":"Health Econ"},{"key":"1318_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","volume":"6","author":"W Yang","year":"2020","unstructured":"Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. Current and projected future economic burden of Parkinson\u2019s disease in the US. NPJ Parkinsons Dis. 2020;6:15.","journal-title":"NPJ Parkinsons Dis."},{"key":"1318_CR22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ahj.2003.10.006","volume":"147","author":"L Liao","year":"2004","unstructured":"Liao L, Whellan DJ, Tabuchi K, Schulman KA. Differences in care-seeking behavior for acute chest pain in the United States and Japan. Am Heart J. 2004;147:630\u20135.","journal-title":"Am Heart J"},{"key":"1318_CR23","doi-asserted-by":"crossref","unstructured":"Arias E, Tejada-Vera B, Kochanek K, Ahmad F. Vital statistics rapid release: provisional life expectancy estimates for 2021. Centers for Disease Control and Prevention; 2022. Available from: https:\/\/www.cdc.gov\/nchs\/data\/vsrr\/vsrr023.pdf. Accessed 12 Sep 2023.","DOI":"10.15620\/cdc:118999"},{"key":"1318_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0168-8510(91)90142-K","volume":"18","author":"RG Brooks","year":"1991","unstructured":"Brooks RG, Jendteg S, Lindgren B, Persson U, Bj\u00f6rk S. EuroQol: health-related quality of life measurement. Results of the Swedish questionnaire exercise. Health Policy. 1991;18:37\u201348.","journal-title":"Health Policy"},{"key":"1318_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0168-8510(91)90141-J","volume":"18","author":"E Nord","year":"1991","unstructured":"Nord E. EuroQol: health-related quality of life measurement: valuations of health states by the general public in Norway. Health Policy. 1991;18:25\u201336.","journal-title":"Health Policy"},{"key":"1318_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/BF02956350","volume":"6","author":"J-M Graf","year":"1998","unstructured":"Graf J-M, Claes C, Greiner W, Uber A. Die deutsche Version des EuroQol-Fragebogens. J Public Health. 1998;6:3\u201320.","journal-title":"J Public Health"},{"key":"1318_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0272989X0002000304","volume":"20","author":"JA Johnson","year":"2000","unstructured":"Johnson JA, Ohinmaa A, Murti B, Sintonen H, Coons SJ. Comparison of Finnish and US-based visual analog scale valuations of the EQ-5D measure. Med Decis Mak. 2000;20:281\u20139.","journal-title":"Med Decis Mak."},{"key":"1318_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/hec.673","volume":"11","author":"A Tsuchiya","year":"2002","unstructured":"Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11:341\u201353.","journal-title":"Health Econ"},{"key":"1318_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jclinepi.2012.04.012","volume":"66","author":"M Brunetti","year":"2013","unstructured":"Brunetti M, Shemilt I, Pregno S, Vale L, Oxman AD, Lord J, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol. 2013;66:140\u201350.","journal-title":"J Clin Epidemiol."},{"key":"1318_CR30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.wneu.2014.08.051","volume":"82","author":"XL Zhu","year":"2014","unstructured":"Zhu XL, Chan DTM, Lau CKY, Poon WS, Mok VCT, Chan AYY, et al. Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study. World Neurosurg. 2014;82:987\u201393.","journal-title":"World Neurosurg."},{"key":"1318_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1525-1403.2005.05233.x","volume":"8","author":"J Yianni","year":"2005","unstructured":"Yianni J, Green AL, McIntosh E, Bittar RG, Joint C, Scott R, et al. The costs and benefits of deep brain stimulation surgery for patients with dystonia: an initial exploration. Neuromodulation. 2005;8:155\u201361.","journal-title":"Neuromodulation"},{"key":"1318_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3111\/13696998.2014.979937","volume":"18","author":"E Walter","year":"2015","unstructured":"Walter E, Odin P. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson\u2019s disease in the UK and Germany. J Med Econ. 2015;18:155\u201365.","journal-title":"J Med Econ"},{"key":"1318_CR33","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/mds.21652","volume":"22","author":"F Valldeoriola","year":"2007","unstructured":"Valldeoriola F, Morsi O, Tolosa E, Rumia J, Marti MJ, Martinez-Martin P. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson\u2019s disease. Move Disord. 2007;22:2183\u201391.","journal-title":"Move Disord."},{"key":"1318_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/ner.12474","volume":"19","author":"JB Pietzsch","year":"2016","unstructured":"Pietzsch JB, Garner AM, Marks WJ. Cost-effectiveness of deep brain stimulation for advanced Parkinson\u2019s disease in the United States. Neuromodulation. 2016;19:689\u201397.","journal-title":"Neuromodulation"},{"key":"1318_CR35","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/mds.26423","volume":"31","author":"E McIntosh","year":"2016","unstructured":"McIntosh E, Gray A, Daniels J, Gill S, Ives N, Jenkinson C, et al. Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson\u2019s: economic evaluation alongside the PD SURG trial. Move Disord. 2016;31:1173\u201382.","journal-title":"Move Disord."},{"key":"1318_CR36","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.wneu.2015.11.062","volume":"89","author":"Y Kawamoto","year":"2016","unstructured":"Kawamoto Y, Mouri M, Taira T, Iseki H, Masamune K. Cost-effectiveness analysis of deep brain stimulation in patients with Parkinson\u2019s disease in Japan. World Neurosurg. 2016;89:628.","journal-title":"World Neurosurg."},{"key":"1318_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159340","volume":"11","author":"T Fundament","year":"2016","unstructured":"Fundament T, Eldridge PR, Green AL, Whone AL, Taylor RS, Williams AC, et al. Deep brain stimulation for Parkinson\u2019s disease with early motor complications: a UK cost-effectiveness analysis. PLoS ONE. 2016;11: e0159340.","journal-title":"PLoS ONE"},{"key":"1318_CR38","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/j.wneu.2020.02.150","volume":"138","author":"JC-Y Fann","year":"2020","unstructured":"Fann JC-Y, Chang K-C, Yen AM-F, Chen SL-S, Chiu SY-H, Chen H-H, et al. Cost-effectiveness analysis of deep brain stimulation for Parkinson disease in Taiwan. World Neurosurg. 2020;138:e459\u201368.","journal-title":"World Neurosurg."},{"key":"1318_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s00415-013-7148-z","volume":"261","author":"S Eggington","year":"2014","unstructured":"Eggington S, Valldeoriola F, Chaudhuri KR, Ashkan K, Annoni E, Deuschl G. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson\u2019s disease. J Neurol. 2014;261:106\u201316.","journal-title":"J Neurol"},{"key":"1318_CR40","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/mds.26740","volume":"31","author":"J Dams","year":"2016","unstructured":"Dams J, Balzer-Geldsetzer M, Siebert U, Schnitzler A, Reese J-P, Dodel R, et al. Cost-effectiveness of neurostimulation in Parkinson\u2019s disease with early motor complications. Move Disord. 2016;31:1183\u201391.","journal-title":"Move Disord."},{"key":"1318_CR41","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/mds.25407","volume":"28","author":"J Dams","year":"2013","unstructured":"Dams J, Siebert U, Bornschein B, Volkmann J, Deuschl G, Oertel WH, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson\u2019s disease. Move Disord. 2013;28:763\u201371.","journal-title":"Move Disord."},{"key":"1318_CR42","doi-asserted-by":"publisher","unstructured":"Guo X, Feng C, Pu J, Jiang H, Zhu Z, Zheng Z, et al. Deep brain stimulation for advanced Parkinson disease in developing countries: a cost-effectiveness study from China. Neurosurgery. 2022. https:\/\/doi.org\/10.1227\/neu.0000000000002274. Epub ahead of print. Accessed 23 Mar 2023.","DOI":"10.1227\/neu.0000000000002274"},{"key":"1318_CR43","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/mds.870130306","volume":"13","author":"EA Chrischilles","year":"1998","unstructured":"Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL. The health burdens of Parkinson\u2019s disease. Mov Disord. 1998;13:406\u201313.","journal-title":"Mov Disord"},{"key":"1318_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1600-0404.1977.tb01420.x","volume":"56","author":"RJ Marttila","year":"1977","unstructured":"Marttila RJ, Rinne UK. Disability and progression in Parkinson\u2019s disease. Acta Neurol Scand. 1977;56:159\u201369.","journal-title":"Acta Neurol Scand"},{"key":"1318_CR45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427\u201342.","journal-title":"Neurology"},{"key":"1318_CR46","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Sch\u00e4fer H, B\u00f6tzel K, et al. A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med. 2006;355:896\u2013908.","journal-title":"N Engl J Med"},{"key":"1318_CR47","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1474-4422(10)70093-4","volume":"9","author":"A Williams","year":"2010","unstructured":"Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson\u2019s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 2010;9:581\u201391.","journal-title":"Lancet Neurol"},{"key":"1318_CR48","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3111\/13696998.2011.598201","volume":"14","author":"J Lowin","year":"2011","unstructured":"Lowin J, Bergman A, Chaudhuri KR, Findley LJ, Roeder C, Schifflers M, et al. A cost-effectiveness analysis of levodopa\/carbidopa intestinal gel compared to standard care in late stage Parkinson\u2019s disease in the UK. J Med Econ. 2011;14:584\u201393.","journal-title":"J Med Econ"},{"key":"1318_CR49","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1185\/030079905X49653","volume":"21","author":"LJ Findley","year":"2005","unstructured":"Findley LJ, Lees A, Apajasalo M, Pitk\u00e4nen A, Turunen H. Cost-effectiveness of levodopa\/carbidopa\/entacapone (Stalevo) compared to standard care in UK Parkinson\u2019s disease patients with wearing-off. Curr Med Res Opin. 2005;21:1005\u201314.","journal-title":"Curr Med Res Opin"},{"key":"1318_CR50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.parkreldis.2012.07.004","volume":"19","author":"G Deuschl","year":"2013","unstructured":"Deuschl G, Sch\u00fcpbach M, Knudsen K, Pinsker MO, Cornu P, Rau J, et al. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson\u2019s disease: concept and standards of the EARLYSTIM-study. Parkinsonism Related Disord. 2013;19:56\u201361.","journal-title":"Parkinsonism Related Disord."},{"key":"1318_CR51","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1345\/aph.1G454","volume":"40","author":"J Hudry","year":"2006","unstructured":"Hudry J, Rinne JO, Ker\u00e4nen T, Eckert L, Cochran JM. Cost-utility model of rasagiline in the treatment of advanced Parkinson\u2019s disease in Finland. Ann Pharmacother. 2006;40:651\u20137.","journal-title":"Ann Pharmacother"},{"key":"1318_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1212\/WNL.0b013e31825dcdc1","volume":"79","author":"FM Weaver","year":"2012","unstructured":"Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012;79:55\u201365.","journal-title":"Neurology"},{"key":"1318_CR53","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/geront\/gnr151","volume":"52","author":"AA Bohl","year":"2012","unstructured":"Bohl AA, Phelan EA, Fishman PA, Harris JR. How are the costs of care for medical falls distributed? The costs of medical falls by component of cost, timing, and injury severity. Gerontologist. 2012;52:664\u201375.","journal-title":"Gerontologist"},{"key":"1318_CR54","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mds.22875","volume":"25","author":"YJ Zhao","year":"2010","unstructured":"Zhao YJ, Wee HL, Chan Y-H, Seah SH, Au WL, Lau PN, et al. Progression of Parkinson\u2019s disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord. 2010;25:710\u20136.","journal-title":"Mov Disord"},{"key":"1318_CR55","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1023\/A:1008903126315","volume":"9","author":"CS Palmer","year":"2000","unstructured":"Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for \u201coff-time\u201d outcomes in the treatment of Parkinson\u2019s disease. Qual Life Res. 2000;9:819\u201327.","journal-title":"Qual Life Res"},{"key":"1318_CR56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2753.2008.01041.x","volume":"15","author":"H-H Liou","year":"2009","unstructured":"Liou H-H, Wu C-Y, Chiu Y-H, Yen AM-F, Chen R-C, Chen T-F, et al. Mortality of Parkinson\u2019s disease by Hoehn-Yahr stage from community-based and clinic series [Keelung Community-based Integrated Screening (KCIS) no. 17)]. J Eval Clin Pract. 2009;15:587\u201391.","journal-title":"J Eval Clin Pract"},{"key":"1318_CR57","unstructured":"The World Bank. Life expectancy at birth, total (years). 2020. Available from: https:\/\/data.worldbank.org\/indicator\/SP.DYN.LE00.IN?view=chart. Accessed 12 Sep 2023."},{"key":"1318_CR58","doi-asserted-by":"crossref","unstructured":"Massetti M, Aball\u00e9a S, Videau Y, R\u00e9muzat C, Ro\u00efz J, Toumi M. A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments. J Mark Access Health Policy. 2015;3.","DOI":"10.3402\/jmahp.v3.24966"},{"key":"1318_CR59","unstructured":"Institute for Clinical and Economic Review. 2020\u20132023 value assessment framework. 2022. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/11\/ICER_2020_2023_VAF_02032022.pdf. Accessed 11 Mar 2023."},{"key":"1318_CR60","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword. Accessed 11 Mar 2023."},{"key":"1318_CR61","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Choices in methods for economic evaluation: HAS. 2020. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-11\/methodological_guidance_2020_-choices_in_methods_for_economic_evaluation.pdf. Accessed 11 Mar 2023."},{"key":"1318_CR62","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","volume":"368","author":"WMM Schuepbach","year":"2013","unstructured":"Schuepbach WMM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, et al. Neurostimulation for Parkinson\u2019s disease with early motor complications. N Engl J Med. 2013;368:610\u201322.","journal-title":"N Engl J Med"},{"key":"1318_CR63","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/mds.29052","volume":"37","author":"P Mahlknecht","year":"2022","unstructured":"Mahlknecht P, Foltynie T, Limousin P, Poewe W. How does deep brain stimulation change the course of Parkinson\u2019s disease? Move Disord. 2022;37:1581\u201392.","journal-title":"Move Disord."},{"key":"1318_CR64","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/mds.23903","volume":"26","author":"M Zibetti","year":"2011","unstructured":"Zibetti M, Merola A, Rizzi L, Ricchi V, Angrisano S, Azzaro C, et al. Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson\u2019s disease. Mov Disord. 2011;26:2327\u201334.","journal-title":"Mov Disord"},{"key":"1318_CR65","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.parkreldis.2014.01.012","volume":"20","author":"MG Rizzone","year":"2014","unstructured":"Rizzone MG, Fasano A, Daniele A, Zibetti M, Merola A, Rizzi L, et al. Long-term outcome of subthalamic nucleus DBS in Parkinson\u2019s disease: from the advanced phase towards the late stage of the disease? Parkinsonism Relat Disord. 2014;20:376\u201381.","journal-title":"Parkinsonism Relat Disord"},{"key":"1318_CR66","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/mdc3.12965","volume":"7","author":"A Fasano","year":"2020","unstructured":"Fasano A, Antonini A, Katzenschlager R, Krack P, Odin P, Evans AH, et al. Management of advanced therapies in Parkinson\u2019s disease patients in times of humanitarian crisis: the COVID -19 experience. Mov Disord Clin Pract. 2020;7:361\u201372.","journal-title":"Mov Disord Clin Pract."},{"key":"1318_CR67","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1136\/jnnp-2013-305271","volume":"85","author":"A Merola","year":"2014","unstructured":"Merola A, Rizzi L, Zibetti M, Artusi CA, Montanaro E, Angrisano S, et al. Medical therapy and subthalamic deep brain stimulation in advanced Parkinson\u2019s disease: a different long-term outcome? J Neurol Neurosurg Psychiatry. 2014;85:552\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1318_CR68","doi-asserted-by":"publisher","first-page":"e2559","DOI":"10.1212\/WNL.0000000000007562","volume":"92","author":"B Lau","year":"2019","unstructured":"Lau B, Meier N, Serra G, Czernecki V, Schuepbach M, Navarro S, et al. Axial symptoms predict mortality in patients with Parkinson disease and subthalamic stimulation. Neurology. 2019;92:e2559\u201370.","journal-title":"Neurology"},{"key":"1318_CR69","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00415-021-10430-y","volume":"268","author":"MA Volont\u00e9","year":"2021","unstructured":"Volont\u00e9 MA, Clarizio G, Galantucci S, Scamarcia PG, Cardamone R, Barzaghi LR, et al. Long term follow-up in advanced Parkinson\u2019s disease treated with DBS of the subthalamic nucleus. J Neurol. 2021;268:2821\u201330.","journal-title":"J Neurol"},{"key":"1318_CR70","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/ane.12342","volume":"131","author":"B Lilleeng","year":"2015","unstructured":"Lilleeng B, Gjerstad M, Baardsen R, Dalen I, Larsen JP. Motor symptoms after deep brain stimulation of the subthalamic nucleus. Acta Neurol Scand. 2015;131:298\u2013304.","journal-title":"Acta Neurol Scand"},{"key":"1318_CR71","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012246","author":"F Bove","year":"2021","unstructured":"Bove F, Mulas D, Cavallieri F, Castrioto A, Chabard\u00e8s S, Meoni S, et al. Long-term outcomes (15 years) after subthalamic nucleus deep brain stimulation in patients with Parkinson disease. Neurology. 2021. https:\/\/doi.org\/10.1212\/WNL.0000000000012246.","journal-title":"Neurology"},{"key":"1318_CR72","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1001\/archneurol.2011.182","volume":"68","author":"A Castrioto","year":"2011","unstructured":"Castrioto A, Lozano AM, Poon Y-Y, Lang AE, Fallis M, Moro E. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol. 2011;68:1550\u20136.","journal-title":"Arch Neurol"},{"key":"1318_CR73","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41582-019-0145-9","volume":"15","author":"P Limousin","year":"2019","unstructured":"Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nat Rev Neurol. 2019;15:234\u201342.","journal-title":"Nat Rev Neurol"},{"key":"1318_CR74","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.parkreldis.2019.03.009","volume":"64","author":"ML Lachenmayer","year":"2019","unstructured":"Lachenmayer ML, Bettschen C, Bernasconi C, Petermann K, Debove I, Muellner J, et al. Stimulation of the globus pallidus internus in the treatment of Parkinson\u2019s disease: long-term results of a monocentric cohort. Parkinsonism Relat Disord. 2019;64:118\u201323.","journal-title":"Parkinsonism Relat Disord"},{"key":"1318_CR75","doi-asserted-by":"crossref","unstructured":"Tsuboi T, Lemos Melo Lobo Jofili Lopes J, Moore K, Patel B, Legacy J, Ratajska AM, et al. Long-term clinical outcomes of bilateral GPi deep brain stimulation in advanced Parkinson\u2019s disease: 5 years and beyond. J Neurosurg. 2020:1\u201310.","DOI":"10.3171\/2020.6.JNS20617"},{"key":"1318_CR76","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/jnnp-2017-316373","volume":"89","author":"M Abbes","year":"2018","unstructured":"Abbes M, Lhomm\u00e9e E, Thobois S, Klinger H, Schmitt E, Bichon A, et al. Subthalamic stimulation and neuropsychiatric symptoms in Parkinson\u2019s disease: results from a long-term follow-up cohort study. J Neurol Neurosurg Psychiatry. 2018;89:836.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1318_CR77","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00415-016-8077-4","volume":"263","author":"E Lezcano","year":"2016","unstructured":"Lezcano E, G\u00f3mez-Esteban JC, Tijero B, Bilbao G, Lambarri I, Rodriguez O, et al. Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson\u2019s disease. J Neurol. 2016;263:895\u2013905.","journal-title":"J Neurol"},{"key":"1318_CR78","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2307\/1885909","volume":"37","author":"A Pigou","year":"1922","unstructured":"Pigou A. The foreign exchanges. Q J Econ. 1922;37:52\u201374.","journal-title":"Q J Econ"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01318-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01318-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01318-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T16:25:58Z","timestamp":1705422358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01318-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01318-y","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"28 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funds, grants, or other support were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Melissa Lannon, Taylor Duda, Alexander Mastrolonardo, Ellissa Huang, Amanda Martyniuk, Forough Farrokhyar, Feng Xie, Mohit Bhandari, Suneil K. Kalia, and Sunjay Sharma have no relevant financial or non-financial interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data utilized in this study have been collected from previously published literature (systematic review), therefore no ethical approval is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All data utilized in this study have been collected from previously published literature, therefore informed consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All data utilized in this study has been collected from previously published literature, therefore consent for publication is not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. ML, TD, AM, FF, SK, and SS conceived of the idea. The literature search was performed by ML and TD in collaboration with a medical librarian. Screening and data abstraction were performed by ML, TD, EH, AM, and AM. Statistical analyses were performed by ML and FF. The first draft of the manuscript was written by ML and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}